These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 37855338)

  • 1. SGLT-2 Inhibitors: The Next-generation Treatment for Type 2 Diabetes Mellitus.
    Lukic N; Macvanin MT; Gluvic Z; Rizzo M; Radak D; Suri JS; Isenovic ER
    Curr Med Chem; 2023 Oct; ():. PubMed ID: 37855338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
    Derosa G; Maffioli P
    Ther Clin Risk Manag; 2018; 14():1637-1640. PubMed ID: 30237717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardio-renal protection with empagliflozin.
    MacIsaac RJ; Jerums G; Ekinci EI
    Ann Transl Med; 2016 Oct; 4(20):409. PubMed ID: 27867961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative safety of different sodium-glucose transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.
    Li CX; Liu LY; Zhang CX; Geng XH; Gu SM; Wang YQ; Liu H; Xie Q; Liang S
    Front Endocrinol (Lausanne); 2023; 14():1238399. PubMed ID: 37701900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
    Seferović PM; Coats AJS; Ponikowski P; Filippatos G; Huelsmann M; Jhund PS; Polovina MM; Komajda M; Seferović J; Sari I; Cosentino F; Ambrosio G; Metra M; Piepoli M; Chioncel O; Lund LH; Thum T; De Boer RA; Mullens W; Lopatin Y; Volterrani M; Hill L; Bauersachs J; Lyon A; Petrie MC; Anker S; Rosano GMC
    Eur J Heart Fail; 2020 Feb; 22(2):196-213. PubMed ID: 31816162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.
    Aftab S; Vetrivel Suresh R; Sherali N; Daniyal M; Tsouklidis N
    Cureus; 2020 Oct; 12(10):e10783. PubMed ID: 33042651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.
    Semo D; Obergassel J; Dorenkamp M; Hemling P; Strutz J; Hiden U; Müller N; Müller UA; Zulfikar SA; Godfrey R; Waltenberger J
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and Cardiorenal Complications: A Clinical Review of Existing Therapies and Novel Combinations, Focusing on SGLT2 Inhibitors.
    Kale A; Sharma A; Anders HJ; Gaikwad AB
    Curr Diabetes Rev; 2023; 19(8):e160822207546. PubMed ID: 35975848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study.
    Paul SK; Bhatt DL; Montvida O
    Eur Heart J; 2021 May; 42(18):1728-1738. PubMed ID: 33289789
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
    Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
    Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 14. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India.
    Fatima Z; Atal S; Joshi R; Sadasivam B
    Cureus; 2022 Feb; 14(2):e22141. PubMed ID: 35308676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus.
    Mirabelli M; Chiefari E; Caroleo P; Vero R; Brunetti FS; Corigliano DM; Arcidiacono B; Foti DP; Puccio L; Brunetti A
    J Diabetes Res; 2019; 2019():3971060. PubMed ID: 31781664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 Inhibitor Use in Heart Failure: A Review for Nurses.
    March KL; Lukas JG; Berei TJ; Shah SP; Cave BE
    Crit Care Nurs Q; 2022 Apr-Jun 01; 45(2):189-198. PubMed ID: 35212658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
    Schwartz SS; Ahmed I
    Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.
    Zhou B; Shi Y; Fu R; Ni H; Gu L; Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
    Front Endocrinol (Lausanne); 2022; 13():907340. PubMed ID: 35692406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
    Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
    Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.